BRIEF-Salarius Pharmaceuticals Says Now Determined To Close Ongoing Phase 1/2 Clinical Trial Evaluating Seclidemstat For Ewing Sarcoma

Reuters07-20

July 19 (Reuters) - Salarius Pharmaceuticals Inc

* SALARIUS PHARMACEUTICALS INC: NOW DETERMINED TO CLOSE ONGOING PHASE 1/2 CLINICAL TRIAL EVALUATING SECLIDEMSTAT FOR EWING SARCOMA

* SALARIUS PHARMACEUTICALS INC - TERMINATING THE ONGOING CLINICAL TRIAL IN AN EFFORT TO CONSERVE CASH

* SALARIUS PHARMACEUTICALS INC: CONTINUES ITS EXPLORATION OF POTENTIAL STRATEGIC ALTERNATIVES

* SALARIUS PHARMACEUTICALS: TO CONTINUE SUPPORT FOR MDACC'S SPONSORED CLINICAL TRIAL EVALUATING SECLIDEMSTAT (SP-2577) IN COMBINATION WITH AZACITIDINE

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2452871281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-20 05:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2452871281","market":"us","top_or_hot":-1,"title":"BRIEF-Salarius Pharmaceuticals Says Now Determined To Close Ongoing Phase 1/2 Clinical Trial Evaluating Seclidemstat For Ewing Sarcoma","media":"Reuters","content":"<html><body><p>July 19 (Reuters) - <a href=\"https://laohu8.com/S/SLRX\">Salarius Pharmaceuticals Inc</a></p><p> :</p><p>   * SALARIUS PHARMACEUTICALS INC: NOW DETERMINED TO CLOSE ONGOING PHASE 1/2 CLINICAL TRIAL EVALUATING SECLIDEMSTAT FOR EWING SARCOMA</p><p>   * SALARIUS PHARMACEUTICALS INC - TERMINATING THE ONGOING CLINICAL TRIAL IN AN EFFORT TO CONSERVE CASH</p><p>   * SALARIUS PHARMACEUTICALS INC: CONTINUES ITS EXPLORATION OF POTENTIAL STRATEGIC ALTERNATIVES</p><p>   * SALARIUS PHARMACEUTICALS: TO CONTINUE SUPPORT FOR MDACC'S SPONSORED CLINICAL TRIAL EVALUATING SECLIDEMSTAT (SP-2577) IN COMBINATION WITH AZACITIDINE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Salarius Pharmaceuticals Says Now Determined To Close Ongoing Phase 1/2 Clinical Trial Evaluating Seclidemstat For Ewing Sarcoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Salarius Pharmaceuticals Says Now Determined To Close Ongoing Phase 1/2 Clinical Trial Evaluating Seclidemstat For Ewing Sarcoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-20 05:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 19 (Reuters) - Salarius Pharmaceuticals Inc :   * SALARIUS PHARMACEUTICALS INC: NOW DETERMINED TO CLOSE ONGOING PHASE 1/2 CLINICAL TRIAL EVALUATING SECLIDEMSTAT FOR EWING SARCOMA   * SALARIUS ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLRX","symbol_name":"Salarius Pharmaceuticals Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2452871281","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2452871281","pubTimestamp":1721424006,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"July 19  - Salarius Pharmaceuticals Inc :   * SALARIUS PHARMACEUTICALS INC: NOW DETERMINED TO CLOSE ONGOING PHASE 1/2 CLINICAL TRIAL EVALUATING SECLIDEMSTAT FOR EWING SARCOMA   * SALARIUS PHARMACEUTICALS INC - TERMINATING THE ONGOING CLINICAL TRIAL IN AN EFFORT TO CONSERVE CASH   * SALARIUS PHARMACEUTICALS INC: CONTINUES ITS EXPLORATION OF POTENTIAL STRATEGIC ALTERNATIVES   * SALARIUS PHARMACEUTICALS: TO CONTINUE SUPPORT FOR MDACC'S SPONSORED CLINICAL TRIAL EVALUATING SECLIDEMSTAT  IN COMBINATION WITH AZACITIDINESource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLRX":"Salarius Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"简介-Salarius Pharmaceuticals表示现已决定结束正在进行的评估Seclidemstat治疗尤文肉瘤的1/2期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLRX":0.9},"content_text":"July 19 (Reuters) - Salarius Pharmaceuticals Inc :   * SALARIUS PHARMACEUTICALS INC: NOW DETERMINED TO CLOSE ONGOING PHASE 1/2 CLINICAL TRIAL EVALUATING SECLIDEMSTAT FOR EWING SARCOMA   * SALARIUS PHARMACEUTICALS INC - TERMINATING THE ONGOING CLINICAL TRIAL IN AN EFFORT TO CONSERVE CASH   * SALARIUS PHARMACEUTICALS INC: CONTINUES ITS EXPLORATION OF POTENTIAL STRATEGIC ALTERNATIVES   * SALARIUS PHARMACEUTICALS: TO CONTINUE SUPPORT FOR MDACC'S SPONSORED CLINICAL TRIAL EVALUATING SECLIDEMSTAT (SP-2577) IN COMBINATION WITH AZACITIDINESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452871281"}